Posted by Michael Wonder on 02 May 2019
ICER posts draft scoping document for the assessment of treatments for type 2 diabetes mellitus
2 May 2019 - Document open to public comment until 22 May 2019.
The ICER has posted a draft scoping document outlining a planned review of the comparative clinical effectiveness and value of oral semaglutide (Novo Nordisk) and other treatments for type 2 diabetes mellitus.
The report will compare oral semaglutide, a GLP-1 agonist, to three products currently on the market: liraglutide (Victoza, Novo Nordisk), another GLP-1 agonist; empagliflozin (Jardiance, Boehringer Ingelheim and Eli Lilly), a SGLT-2 inhibitor; and sitagliptin (Januvia, Merck), a DPP-4 inhibitor.
